Clin2
NCT07448181Possibly a fitRecruiting

Daily tracking of hereditary angioedema burden

Hereditary Angioedema With C1 Esterase Inhibitor DeficiencyHereditary Angioedema - Type 1Hereditary Angioedema - Type 2

Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.

This study uses a smartphone app to track how hereditary angioedema affects your daily life over 8 weeks. It aims to better understand the real-world burden of the condition and may help improve care.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
30 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You have been diagnosed with type 1 or type 2 hereditary angioedema (HAE).
  • You are 18 years old or older.
  • You own and can use a personal smartphone that works with the m-Path app (Android or iPhone).
  • You are willing to use the app and answer daily questions for 8 weeks.
  • You do not have other types of angioedema or severe mental health issues that would prevent you from completing the questionnaires.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05396105Enrolling by invitation· Phase 2/Phase 3
Oral PHA-022121 extension for hereditary angioedema attacks

This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.

Birmingham, Alabama
NCT05833620Not yet recruiting
Genetic study of hereditary angioedema causes

This study looks for genetic changes that may explain hereditary angioedema (HAE) and how C1 inhibitor (C1INH) works. Your participation may help researchers better understand what causes symptoms and who is affected.

Barcelona
NCT06960213Recruiting· Phase 3
Study of ADX-324 for preventing HAE attacks

This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.

Litchfield Park, Arizona
NCT06655337Recruiting
Testing a smartphone app for managing hospital discharge

This study tests whether a smartphone app called Medidux helps you manage your symptoms and discharge from the hospital if you came in with coughing, back pain, or belly discomfort. You'll use the app to report how you're feeling, and the care team can check in with you after you leave.

Horgen, Canton of Zurich
NCT06670677Recruiting
Blood pressure monitoring for early heart risk awareness

This study is testing whether a blood pressure monitoring system called Aktiia can help people become aware of high blood pressure early and predict heart risks. It involves using a smartphone and a wrist bracelet (or just the phone's camera) to take blood pressure readings.

Lausanne
NCT07293364Recruiting
Study of C1-inhibitor test for hereditary angioedema diagnosis

This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.

Algiers

Hear when a new Hereditary Angioedema With C1 Esterase Inhibitor Deficiency trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.